US 2023/0087871 A1Published application

Antitumor combinations containing anti-ceacam5 antibody conjugates and folfiri

AssigneeSanofi

InventorCéline NICOLAZZI

Life of this patent

Estimating the term…

Abstract

The present invention concerns antibody-conjugates comprising an anti-CEACAM5-antibody for use for treating cancer in combination with folinic acid, 5-fluoro-uracil and irinotecan (FOLFIRI). The invention further relates to pharmaceutical compositions and kit-of-parts comprising an anti-CEACAM5-antibody in combination with folinic acid, 5-fluoro-uracil and irinotecan (FOLFIRI) for use for treating cancer.

Claims22

Dependent claims

An immunoconjugate comprising an anti-CEACAM5-antibody for use for treating cancer in combination with folinic acid, 5-fluoro-uracil and irinotecan (FOLFIRI).

Dependencies are inferred from the claim text.

Facts

Application: 17/916,877Filed 22 Apr 2021
Priority: EP 20315219.424 Apr 2020
Published: 23 Mar 2023
Term ends: Not estimatedThe source records don’t support an estimate.

Classification12 codes

A61K 47/6895
Pre-targeting systems involving an antibody for targeting specific cells: rescue therapy; Agonist-antagonist; Antidotes; Targeted rescue or…
A61K 31/4745
Ortho- or peri-condensed with heterocyclic ring systems: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
A61K 31/513
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/519
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim: ortho- or peri-condensed with heterocyclic rings

Family

No related US applications are recorded in the indexed filing history.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results